

Curriculum Vitae

I. PERSONAL DATA

First Name James
Last name Luyendyk
Current Academic Rank Associate Professor
Department(s) Pathobiology and Diagnostic Investigation
Office Address 253 Food Safety Toxicology
Phone 517-884-2057
Fax 517-432-2310
Email luyendyk@msu.edu

PROFESSIONAL DEVELOPMENT

Undergraduate and Graduate Education

| Years (Inclusive) | Degree | Institution |
|-------------------|---|--|
| 1996-2000 | B.S., Biochemistry | Colorado State University, Fort Collins, CO |
| 2000-2004 | Ph.D., Pharmacology/Toxicology- Environmental Toxicology Advisor: Robert A. Roth Dissertation title: Inflammation and Idiosyncratic Drug Reactions | Michigan State University, East Lansing, MI Department of Pharmacology and Toxicology, Institute for Environmental Toxicology |

Postgraduate Education

| Years (Inclusive) | Degree | Institution |
|-------------------|---|--|
| 2005 | Research Associate (Supervisor: Robert A. Roth, Ph.D.) | Michigan State University, East Lansing, MI Department of Pharmacology and Toxicology, Institute for Environmental Toxicology |
| 2005 | Research Associate (Supervisor: Nigel Mackman, Ph.D.) | The Scripps Research Institute, La Jolla, CA Department of Immunology |
| 2006-2007 | NIH Individual National Research Service Award Postdoctoral Fellow (Supervisor: Nigel Mackman, Ph.D.) | The Scripps Research Institute, La Jolla, CA Department of Immunology |

Academic and Professional Appointments and Activities

| Month and Year | Position | Institution |
|----------------|----------------------------|---|
| 07/07-2/12 | Assistant Professor | University of Kansas Medical Center, Kansas City, KS Department of Pharmacology, Toxicology and Therapeutics |
| 03/12-present | Associate Professor | Michigan State University, East Lansing, MI Department of Pathobiology and Diagnostic Investigation |

Professional Societies and Affiliations

| Date | Organization (including offices held) |
|-------------------------|--|
| 2001-2005, 2012-present | Michigan Regional Chapter, Society of Toxicology <u>Offices held:</u> Councilor 2013-2015 |
| 2010-present | American Society for Investigative Pathology, Regular Member |
| 2008-present | American Heart Association, Premium Professional Member |
| 2001-present | Society of Toxicology, Associate Member |
| 2008-2012 | Central States Regional Chapter, Society of Toxicology <u>Offices held:</u> 2009-2011 Councilor |
| 2007-2012 | University of Kansas Medical Center Cancer Center |
| 2007-present | University of Kansas Medical Center Liver Center |
| 2009-2010 | Sigma Xi <u>Offices held:</u> 2009-2010 President, KUMC Chapter |

Honors and Awards (honorary societies, research awards, teaching and other awards)

| Year | Award |
|------|---|
| 2000 | College Award , Undergraduate Research and Creativity Symposium, Colorado State University, Fort Collins, CO |
| 2002 | Victor A. Drill Award , Midwest Regional Chapter of the Society of Toxicology |
| 2002 | Best Poster Presentation , Phi Zeta Research Day, Michigan State University, East Lansing, MI |
| 2003 | Barnett Rosenberg Fellowship in Biological Sciences , Michigan State University, East Lansing MI |
| 2003 | Best Poster Presentation , Michigan Regional Chapter of the Society of Toxicology |

| | |
|------|--|
| 2004 | Novartis Graduate Student Fellowship , Society of Toxicology |
| 2004 | Best Paper Award , Toxicology Division of American Society of Pharmacology and Experimental Therapeutics |
| 2004 | Best Poster Presentation , Michigan Regional Chapter of the Society of Toxicology |
| 2007 | Young Investigator Travel Award , Thrombosis and Vascular Biology Annual Conference, American Heart Association |
| 2007 | Merck Mechanisms Post-doctoral Award , Mechanisms Specialty Section, Society of Toxicology |
| 2009 | Faculty Travel Award , University of Kansas Medical Center, Kansas City, KS |
| 2010 | Faculty Scholar Award , Kansas IDeA Network of Biomedical Research Excellence |

1. Instruction:

Didactic (e.g.: lectures and formal presentations)

| Academic Year | Course | Title | Instruction | | Student | |
|---------------|--------------------------------------|---|-------------------|-------|---------|----------|
| | | | Type | Hours | No | Type |
| 2008 | PTOX 887 | Toxicologic Pathology (NF-kappaB Signaling) | Didactic lectures | 2 | 8 | Graduate |
| 2008 | PTOX 887 | Toxicologic Pathology (Inflammatory Liver Injury) | Didactic lectures | 2 | 8 | Graduate |
| 2009 | PTOX 918 | Toxicology (Skin/Radiation) | Didactic lectures | 2 | 17 | Graduate |
| 2009 | PTOX 918 | Toxicology (Kidney) | Didactic lectures | 2 | 17 | Graduate |
| 2010 | GSMC 855, IGPBS | Cell Communication (Enzyme-coupled Receptors) | Didactic lectures | 4 | 21 | |
| 2010 | Integration and Consolidation Module | Histamine/Serotonin | Didactic Lectures | 1 | ~175 | MS2 |
| 2010 | Integration and Consolidation Module | Prost/Leuk/NSAIDs | Didactic Lectures | 1 | ~175 | MS2 |
| 2010 | Integration and | Asthma | Didactic | 1 | ~175 | MS2 |

| | | | | | | |
|------|--------------------------------------|---|-------------------|---|------|----------|
| | Consolidation Module | | Lectures | | | |
| 2010 | Integration and Consolidation | Arthritis | Didactic Lectures | 1 | ~175 | MS2 |
| 2010 | Integration and Consolidation Module | Allergies/Migraine | Didactic Lectures | 1 | ~175 | MS2 |
| 2010 | Integration and Consolidation Module | GI Drugs | Didactic Lectures | 1 | ~175 | MS2 |
| 2010 | PTOX 887 | Toxicologic Pathology (NF-kappaB Signaling) | Didactic lectures | 2 | 8 | Graduate |
| 2010 | PTOX 887 | Toxicologic Pathology (Inflammatory Liver Injury) | Didactic lectures | 2 | 8 | Graduate |
| 2011 | GSMC 854, IGPBS | Cell Communication (Enzyme-coupled Receptors) | Didactic lectures | 4 | 21 | |
| 2011 | Integration and Consolidation Module | Histamine/Serotonin | Didactic Lectures | 1 | ~175 | MS2 |
| 2011 | Integration and Consolidation Module | Prost/Leuk/NSAIDs | Didactic Lectures | 1 | ~175 | MS2 |
| 2011 | Integration and Consolidation Module | Asthma | Didactic Lectures | 1 | ~175 | MS2 |
| 2011 | Integration and Consolidation | Arthritis | Didactic Lectures | 1 | ~175 | MS2 |
| 2011 | Integration and Consolidation Module | Allergies/Migraine | Didactic Lectures | 1 | ~175 | MS2 |
| 2011 | Integration and | GI Drugs | Didactic | | | |

| | | | | | | |
|------|----------------------|------------------------|-------------------|---|------|----------|
| | Consolidation Module | | Lectures | 1 | ~175 | MS2 |
| 2011 | PTOX 918 | Toxicology (Kidney) | Didactic lectures | 2 | 15 | Graduate |
| 2012 | PDI 851 | Inflammatory Mediators | Didactic lectures | 2 | ~20 | Graduate |
| 2014 | PDI 851 | Inflammatory Mediators | Didactic lectures | 2 | ~20 | Graduate |
| 2014 | PDI 851 | Hemostasis | Didactic lectures | 1 | ~20 | Graduate |

Nondidactic (e.g.: workshops, labs, and discussion groups)

| Academic Year | Course | Title | Instruction | | Student | |
|---------------|------------------------------------|---------------------------------|------------------------|-------|----------------------|-----------------------|
| | | | Type | Hours | No | Type |
| 2008 | PHCL901: Module 9 (IGPBS) | Introduction to Research Ethics | Discussion Group | 8 | 12 | IGPBS-Graduate |
| 2008 | PTOX 887 | Paper discussion | Discussion Group | 2 | 8 | Pharmacology-Graduate |
| 2009 | PHCL901: Module 9 (IGPBS) | Introduction to Research Ethics | Discussion Group | 8 | 12 | IGPBS-Graduate |
| 2009 | PHCL901: Module 9 (IGPBS) | Introduction to Research Ethics | Discussion Group | 8 | 15 | IGPBS-Graduate |
| 2010 | GSMC 855, IGPBS | Paper discussion | Discussion Group | 2 | 21 | |
| 2009 | Integration & Consolidation Module | ANS and Smooth Muscles | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2009 | Integration & Consolidation Module | Cardiovascular Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2009 | Integration & Consolidation Module | Endocrine Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |

| | | | | | | |
|------|------------------------------------|---------------------------------|------------------------|---|----------------------|-----------------------|
| 2009 | Integration & Consolidation Module | CNS Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | Integration & Consolidation Module | ANS and Smooth Muscles | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | Integration & Consolidation Module | Cardiovascular Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | Integration & Consolidation Module | Endocrine Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | Integration & Consolidation Module | CNS Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | Integration & Consolidation Module | Adverse Effects | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2010 | PHCL901: Module 9 (IGPBS) | Introduction to Research Ethics | Discussion Group | 8 | 14 | IGPBS-Graduate |
| 2010 | PTOX 887 | Paper discussion | Discussion Group | 2 | 8 | Pharmacology-Graduate |
| 2011 | Integration & Consolidation Module | ANS and Smooth Muscles | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2011 | Integration & Consolidation Module | Cardiovascular Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2011 | Integration & Consolidation Module | Endocrine Pharmacology | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2011 | Integration & | CNS | Small | | 12/group | |

| | | | | | | |
|------|------------------------------------|---------------------------------|------------------------|---|----------------------|-----------------|
| | Consolidation Module | Pharmacology | Group Discussion | 4 | 2 groups | MS2 |
| 2011 | Integration & Consolidation Module | Adverse Effects | Small Group Discussion | 4 | 12/group 2 groups | MS2 |
| 2011 | PHCL901: Module 9 (IGPBS) | Introduction to Research Ethics | Discussion Group | 8 | 14 | IGPBS-Graduate |
| 2012 | VM 532 | VIPS | Discussion Group | 2 | 6 | CVM-Small group |
| 2013 | VM 532 | VIPS | Discussion Group | 4 | 20 | |

Master's Theses and PhD Dissertations directed

| Year | Student Name | Thesis Title | Degree (Completed/In process) |
|--------------|------------------|---|---|
| 2009-2012 | Bradley Sullivan | Bile duct epithelial cells as mediators of biliary fibrosis | Completed |
| 2011-2012 | Stephanie Bishop | Role of tissue factor in acetaminophen-induced liver injury | In process (switched labs in 2012) |
| 2012-present | Nikita Joshi | Hepatoprotective functions of fibrin(ogen) in experimental biliary injury | In process (anticipated completion summer 2016) |

Supervision of Postdoctoral Fellows

| Year | Fellow Name | Area of Study |
|--------------|--------------|---|
| 2010-2012 | Karen Kassel | AHA Post-doctoral Fellow Mechanisms of fatty liver disease |
| 2012-present | Anna Kopec | Mechanisms of fatty liver disease |
| 2015-present | Letitia Wong | TCE enhancement of autoimmune liver disease |

Advising (Thesis or dissertation committees: student academic group/individual)

| Date | Student or group name | Type of Student/group |
|-----------|-----------------------|---|
| 2007-2011 | Katryn Allen | Doctoral Dissertation Committee (Completed) |

| | | |
|--------------|--------------------------|---|
| 2009-2012 | Clarence (Dave) Williams | Doctoral Dissertation Committee |
| 2009-2012 | Kai Wu | Doctoral Dissertation Committee |
| 2010-2012 | Zidong Fu | Doctoral Dissertation Committee |
| 2011-2012 | Sharon Manley | Doctoral Dissertation Committee |
| 2012-2014 | Kate O'Brien (Phm/Tox) | Doctoral Dissertation Committee |
| 2012-2014 | Kazuhisa Miyakawa (PDI) | Doctoral Dissertation Committee |
| 2013-present | Sarah Corner (PDI) | Doctoral Dissertation Committee (Ongoing) |
| 2013-present | Alex Turley (Phm/Tox) | Doctoral Dissertation Committee (Ongoing) |
| 2014-present | Katherine Roth (Phm/Tox) | Doctoral Dissertation Committee (Ongoing) |
| 2014-present | Kristen Woltman (CMIB) | Doctoral Dissertation Committee (Ongoing) |
| 2015-present | Calvin Pohl (CMIB) | Doctoral Dissertation Committee (Ongoing) |

Summer Undergraduate Research:

| Date | Student or group name | Type of Student/group |
|------|-----------------------|---|
| 2008 | Alyson Baker | ASPET Summer Intern from the Drury University <u>Project:</u> <i>Inhibition of tissue factor expression by IL-10</i> |
| 2009 | Kevin Flanagan | ASPET Summer Intern from Notre Dame <u>Project:</u> <i>Cholangiocyte cytotoxicity is associated with procoagulant microparticle release.</i> |
| 2010 | Alyson Baker | Visiting Medical Student <u>Project:</u> <i>Tissue factor expression by bile duct epithelial cells</i> |
| 2011 | Brittany Watson | ASPET Summer Intern from Georgia State University <u>Project:</u> <i>Thrombin induction of IL-17 in splenocytes</i> |
| 2012 | Briahna Hardaway | Michigan State University (R25-supported) <u>Project:</u> Regulation of tissue factor expression by s-nitrosoglutathione |
| 2013 | Michelle Lopez | Michigan State University Veterinary Student (R25-supported). <u>Project:</u> Mechanisms of tissue factor encryption on hepatocytes |
| 2014 | Anna Wojcicki | University of Minnesota (R25-supported). <u>Project:</u> Decryption of hepatocyte tissue factor by acetaminophen |
| 2015 | Anna Wojcicki | University of Minnesota (R25-supported). <u>Project:</u> Decryption of hepatocyte tissue factor by acetaminophen |
| 2015 | Marie Brake | University of Miami-Ohio (R25-supported). <u>Project:</u> Regulation of macrophage gene induction by fibrinogen |

Summer High School Students:

| Date | Student or group name | Type of Student/group |
|-----------|-----------------------|--|
| 2013-2014 | Kevin Bi | Okemos High School (Research Class) <u>Project:</u> Impact of fibrinogen on macrophage polarization <i>in vitro</i> |
| 2015- | Dora Ivkovich | Okemos High School Visiting K-12 scholar |

SERVICE ACTIVITIES

Ad-hoc reviewer (average 20 manuscripts per year):

Toxicological Sciences
Journal of Pharmacology and Experimental Therapeutics
Arteriosclerosis, Thrombosis and Vascular Biology
Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
International Journal of Biological Sciences
Biochemical Pharmacology
Toxicology and Applied Pharmacology
Liver International
BMC Immunology
BMC Gastroenterology
Journal of Immunology
Hepatology
International Immunopharmacology
American Journal of Pathology
Experimental Biology and Medicine
Journal of Leukocyte Biology
Journal of Clinical Investigation
FASEB Journal
Journal of Biochemical and Molecular Toxicology

Editorial Boards:

2008: *Journal of Thrombosis and Haemostasis* -Editorial Advisory Board

2010-2014: *Arteriosclerosis, Thrombosis and Vascular Biology* Editorial Board

2011- present: *Toxicological Sciences* Editorial Board

2012-present: *Journal of Biochemical and Molecular Toxicology* Editorial Board

Book Review:

Jakowlew, S.B. Transforming growth factor-beta in Cancer Therapy-Volume 1: Basic and Clinical Biology. Humana Press Inc. 2008.

Haley, JD and Gullick, WJ. EGFR Signaling Networks in Cancer Therapy, Humana Press. 2008.

Mousea. Anticoagulants, Antiplatelets, and Thrombolytics, 2nd Edition. Humana Press Inc., 2010

National and Regional Service:

2001-2004 Regional Chapter Representative, Student Advisory Committee, Michigan Regional Chapter Council, Society of Toxicology

2002-2003 Co-chair, Student Advisory Committee, Society of Toxicology

2002-2004 Student Advisory Committee Representative to the Society of Toxicology's Membership Committee

2003-2004 Chair, Student Advisory Committee, Society of Toxicology
2004 Definition of Toxicology Working Group, Society of Toxicology
2004-2005 Chair, Society of Toxicology Post-Doctoral Task Force
2005-2006 Chair, Society of Toxicology Post-Doctoral Assembly
2006-2007 Member, Member Services Strategy Committee, Society of Toxicology
2009 Reviewed abstracts for the International Society of Thrombosis and Haemostasis Conference
2008-2011 Member, Contemporary Concepts in Toxicology Conferences Committee, Society of Toxicology
2009-2011 Councilor, Central States Regional Chapter of the Society of Toxicology
2013-2015 Councilor, Michigan Regional Chapter of the Society of Toxicology
2013-present Chair, Graduate Education Subcommittee, Society of Toxicology
2013-present Member, Task Force on Scientific Events and Special Programs, ASIP
2013-present Member, Society of Toxicology Education Committee

Grant Review Panels:

2012 National Institutes of Health, SEP (ZDK1-GRB8-O1).
2013 American Heart Association, Vas Wall Bio BSc6 Peer Review Study Group
2014 American Heart Association, Vas Wall Bio BSc4 Peer Review Study Group
2014 National Institutes of Health, 2014/10 ZES1 JAB-D (1R) 1
2014 National Institutes of Health, SEP/SRG 2014/05 ZES1 LKB-J (KS) 1
2015 National Institutes of Health, 2015/05 ZES1 LWJ-J (SF)
2015 National Institutes of Health, 2015/10 ZES1 JAB-J (R0)

Symposium organizer/chair:

2013: Experimental Biology 2013, ASPET Program. Symposium “Role of the coagulation cascade in tissue injury and disease”

Academic Service:

Departmental:

KUMC, Department of Pharmacology, Toxicology and Therapeutics, Post-doctoral Committee:

2009-2012 (Member)

2010-2012 (Chair)

The primary focus of this group is to identify and meet the needs of post-doctoral fellows in the Department.

KUMC, Department of Pharmacology, Toxicology and Therapeutics, Mentoring Website Committee:

2009-2010 (Member)

The primary focus of this group is to develop a website dedicated to the mentoring of new faculty in the Department

MSU, Department of Pathobiology and Diagnostic Investigation,

Graduate student grievance committee: 2013-present

Peer review committee: 2013-present

Endocrinology Faculty Search Committee: 2013

Extra-Departmental:

2009-2010 President, Sigma Xi, University of Kansas Medical Center Chapter

2009-2010 Kansas City Heart Walk-American Heart Association

2010-2012 Departmental representative to SOM Faculty Council.

2013-2014 Search Committee, Endowed Professor of Food Ingredient Safety (CRIS)

Grants and contracts

Previous Grants and contracts awarded:

(List in chronological order – oldest first, newest last)

| Principal Investigator | Investigators | Title of Grant | Funding Source | Years | Status |
|------------------------|-------------------------------|---|----------------------------|-------|------------------|
| Klaassen, C.D. | Luyendyk, J.P. | Nuclear Receptors in Liver Health and Disease. 5P20RR021940-02 Role: Project PI Role of FXR in LPS-induced inflammation and coagulation | NIH/NIEHS | 06-11 | Completed |
| Luyendyk, J.P. | Sponsor: Nigel Mackman, Ph.D. | NIH National Research Service Award 1 F32 HL085983-01 PI3K in LPS-induced coagulation and inflammation | NIH/NHLBI | 06-07 | Completed |
| Luyendyk, J.P. | | 03GC AHA Scientist Development Grant 0835121G Role of tissue factor and coagulation in non-alcoholic fatty liver disease | AHA | 08-11 | Completed |
| Kassel, K.M. | Mentor: Luyendyk | Mechanisms of coagulation cascade-dependent hepatic steatosis | American Heart Association | 11-12 | Completed |
| Roth, R.A. | Co-Investigator: | 02GC | NIH/NIDDK | 10-15 | Completed |

| | | | | | |
|--|----------|---|--|--|-------|
| | Luyendyk | R01 DK087886 Dichotomous roles of thrombin in acetaminophen hepatotoxicity | | | (NCE) |
|--|----------|---|--|--|-------|

Current Grants and contracts awarded:
(List in chronological order – oldest first, newest last)

| Principal Investigator | Investigators | Title of Grant | Funding Source | Years | Status |
|------------------------|---------------|---|----------------------------|-------|--------------|
| Luyendyk, J.P. | | 01GC Outstanding New Environmental Scientist Grant R01 ES017537 Mechanisms of xenobiotic-induced biliary inflammation and fibrosis | NIH/NIEHS | 09-16 | Active (NCE) |
| Luyendyk, J.P. | | 02GC R21 ES024470 Mechanisms of fibrosis exacerbation by trichloroethylene in hepatic autoimmunity. | NIH/NIEHS | 14-16 | Active |
| Luyendyk, J.P. | | 04GC | Boehringer Ingelheim, Inc. | 13-15 | Active |
| Luyendyk, J.P. | | 05GC | Conatus Pharma. | 14-16 | Active |
| Luyendyk, J.P. | | R01 DK105099 Novel mechanisms stimulating liver repair after acetaminophen overdose | NIH/NIDDK | 15-19 | Active |

1. Scholarly Publications

- 01PRA - **Luyendyk J**, Olivas OR, Ginger LA and Avery AC. Antigen-presenting cell function during Plasmodium yoelii infection. Infect. Immun. 2002;70:2941-9
- 02PRA - **Luyendyk JP**, Shores KC, Ganey PE and Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B₁ hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 2002;68:220-5
- 03PRA - **Luyendyk JP**, Copple BL, Barton CC, Ganey PE and Roth RA. Augmentation of aflatoxin B₁ hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. Toxicol. Sci. 2003;72:171-81
- 04PRA - **Luyendyk JP**, Maddox JF, Cosma GN, Ganey PE, Cockerell GL and Roth RA. Ranitidine Treatment during a Modest Inflammatory Response Precipitates Idiosyncrasy-like Liver Injury in Rats. J. Pharmacol. Exp. Ther. 2003;307:9-16
- 05PRA - Roth RA, **Luyendyk JP**, Maddox JF, and Ganey PE. Inflammation and Drug Idiosyncrasy-Is There a Connection? J. Pharmacol. Exp. Ther. 2003;307:1-8.
- 06PRA - Harrigan GG, Laplante RH, Cosma GN, Cockerell GL, Goodacre R, Maddox JF, **Luyendyk JP**, Ganey PE, and Roth RA. Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol. Lett. 2003;146:197-205
- 07PRA - **Luyendyk JP**, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, Ganey PE, Roth RA. Gene Expression Analysis Points to Hemostasis in Livers of Rats Cotreated with Lipopolysaccharide and Ranitidine. Toxicol. Sci. 2004;80:203-13
- 08PRA - Ganey PE, **Luyendyk JP**, Maddox JF, and Roth RA. Adverse hepatic drug reactions: Inflammatory episodes as consequence and contributor. Chemico-Biological Interact. 2004;150:35-51
- 09PRA - **Luyendyk JP**, Maddox JF, Green CD, Ganey PE, and Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology. 2004;40:1342-51
- 010PRA - **Luyendyk JP**, Shaw PJ, Green CD, Maddox JF, Ganey PE, Roth RA. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther. 2005;314:1023-31
- 011PRA - Maddox JF, **Luyendyk JP**, Cosma GN, Breau AP, Bible, Jr. RH, Harrigan GG, Goodacre R, Ganey PE, Cantor GH, Cockerell GL, and Roth RA. Metabonomic Evaluation of Idiosyncrasy-like Liver Injury in Rats Cotreated with Ranitidine and Lipopolysaccharide. Toxicol Appl. Pharmacol. 2006;212:35-44
- 012PRA - Bergheim I, **Luyendyk JP**, Steele C, Russell GK, Guo L, Roth RA, and Arteel GE. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther. 2006;316:1053-61
- 013PRA - Waring JF, Liguori MJ, **Luyendyk JP**, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EAG, and Roth RA. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther. 2006;316:1080-7
- 014PRA - **Luyendyk JP**, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor BD, Deng X, Maddox JF, Ganey PE, Roth RA. Coagulation dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J. Pharmacol. Exp. Ther. 2006;317:635-43

015PRA - **Luyendyk JP**, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor BD, Maddox JF, Ganey PE, Roth RA. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. *Toxicol. Sci.* 2006;90:569-585

016PRA - **Luyendyk JP**, Tilley RE, and Mackman N. Genetic susceptibility to thrombosis. *Curr Atheroscler Rep.* 2006;8:193-7.

017PRA - Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, **Luyendyk JP**, Roth RA, and Arteel GE. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. *Gastroenterology* 2006;130:2099-2112

018PRA - Deng X, Stachlewitz RF, Liguori, MJ, Blomme EAG, Waring JF, **Luyendyk JP**, Maddox JF, Ganey PE and Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and endotoxin translocation. *J Pharmacol Exp Ther.* 2006;319:1191-9

019PRA - Rak J, Yu JL, **Luyendyk J**, and Mackman N Oncogenes, Trousseau syndrome and cancer related changes in the coagulome of mice and humans. *Cancer Res.* 2006;66:10643-6.

020PRA - Ganey PE*, **Luyendyk JP***, Newport SW, Eagle TM, Maddox JF, Mackman N and Roth RA. Role of the coagulation system in acetaminophen-induced hepatotoxicity. *Hepatology.* 2007;46:1177-1186
*equal contribution.

021PRA - Deng X, **Luyendyk JP**, Zou W, Lu J, Malle E, Ganey PE, and Roth RA. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. *J. Pharmacol. Exp. Ther.* 2007;322:852-61

022PRA - **Luyendyk JP**, Piper JD, Tencati M, Reddy KR, Holscher T, Zhang R, Luchoomun J, Chen X, Min W, Kunsch C, and Mackman N. A novel class of antioxidant compounds inhibits LPS induction of tissue factor by reducing the activation of ASK1 and MAP kinases. *Arterioscler. Thromb. Vasc. Biol.* 2007;27:1857-63

023PRA - Ghosh M, Wang H, Ai Y, Romeo E, **Luyendyk JP**, Peters JM, Mackman N, Dey SK, Hla T. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. *J. Exp. Med.* 2007;204:2053-61

024PRA - Milsom C, Yu J, May L, Meehan B, Magnus N, Al-Nedawi K, **Luyendyk J**, Weitz J, Klement P, Broze G, Mackman N, and Rak J. The role of tumor- and host-related tissue factor pools in oncogene-driven tumor progression. *Thromb. Res.* 2007;120:S82-91.

025PRA - Tukov FF, **Luyendyk JP**, Ganey PE and Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. *Toxicol. Sci.* 2007;100:267-80

026PRA - Schabbauer G, **Luyendyk J**, Crozat K, Jiang Z, Mackman N, Bahram S, and Georgel P. TLR4/CD14-mediated PI3K activation is an essential component of Interferon-dependant VSV resistance in macrophages. *Mol. Immunol.* 2008;45:2790-6

027PRA - **Luyendyk JP**, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, and Mackman N. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. *Journal of Immunol.* 2008;180:4218-26

028PRA - Kidd LB, Schabbauer GA, **Luyendyk JP**, Holscher TD, Tilley RE, Tencati M, Mackman N. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. *J Pharmacol Exp Ther.* 2008;326:348-53

029PRA - Yu J, May L, Milsom C, Anderson GM, Weitz JI, **Luyendyk J**, Broze G, Mackman N and Rak J. Contribution of host-derived tissue factor to tumor neovascularization. *Arterioscler. Thromb. Vasc. Biol.* 2008;28:1975-81

030PRA - Kong B, **Luyendyk JP**, Tawfik O, and Guo GL. FXR-deficiency Induces Non-alcoholic Steatohepatitis in LDLr-knockout Mice Fed a High-fat Diet. *J Pharmacol Exp Ther.* 2009;328:116-22

031PRA - **Luyendyk JP**, Cantor GH, Kirchhofer D, Mackman N, Copple BL, Wang R. Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice. *Am J Physiol Gastrointest Liver Physiol.* 2009;296:G840-9

032PRA - Deng X, **Luyendyk JP**, Ganey and PE, and Roth RA. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. *Pharmacol Rev.* 2009;61:262-82.

033PRA - Beier JI, **Luyendyk JP**, Guo L, von Montfort C, Staunton DE, and Arteel GE. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. *Hepatology.* 2009;49:1545-53

034PRA - Baker AK, Wang R, Mackman N, **Luyendyk JP**. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. *Mol. Immunol.* 2009;46:2249-55

035PRA - **Luyendyk JP**, Sullivan BP, Guo GL and Wang R. Tissue Factor-Deficiency and Protease Activated Receptor-1-Deficiency Reduce Inflammation Elicited by Diet-Induced Steatohepatitis in Mice. *Am. J. Pathol.* 2010;176:177-86

036PRA - Sullivan BP, Wang R, Tawfik O, **Luyendyk JP**. Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies. *Toxicol Sci.* 2010;115:286-94

037PRA - Moriarty PM, **Luyendyk JP**, Gibson CA, Backes JM. Effect of Low Density Lipoprotein Apheresis on Plasma Levels of Apolipoprotein E4. *Am J. Cardiol.* 2010;105:1585-7

038PRA - Kassel KM, Guo GL, Tawfik O, and **Luyendyk JP**. Monocyte chemoattractant protein-1-deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. *Lab. Invest.* 2010;90:1794-804

039PRA - Sullivan BP, Weinreb PH, Violette SM, and **Luyendyk JP**. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. *Am. J. Pathol.* 2010;177:2837-49

040PRA - **Luyendyk JP**, Mackman N and Sullivan BP. Role of fibrinogen and protease activated receptors in acute xenobiotic-induced cholestatic liver injury. *Toxicol. Sci.* 2010;119:233-43

041PRA - Liguori MJ, Ditewig AC, Maddox JF, **Luyendyk JP**, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Waring JF, Ganey PE, Roth RA, Blomme EA. Comparison of TNF α to Lipopolysaccharide as an Inflammagen to Characterize the Idiosyncratic Hepatotoxicity Potential of Drugs: Trovafloxacin as an Example. *Int J Mol Sci.* 2010;11:4697-714

042PRA - **Luyendyk JP**, Flanagan KC, Williams D, Jaeschke H, Slusser JG, Mackman N and Cantor GC. Tissue factor contributes to neutrophil CD11b expression in alpha-naphthylisothiocyanate-treated mice. *Toxicol Appl Pharm.* 2001;250:256-62

043PRA - **Luyendyk JP**, Kassel KM, Allen K, Guo GL, Li G, Cantor GH and Copple BL. Fibrinogen deficiency increases liver injury and early growth response-1 expression in a model of chronic xenobiotic-induced cholestasis. *Am. J. Pathol.* 2011;178:1117-1125

044PRA - Sullivan BP, Kassel KM, Manley S, Baker AK, **Luyendyk JP**. Regulation of transforming growth factor- β 1-dependent integrin β 6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells. *J Pharmacol Exp Ther.* 2011;37:471-8

045PRA - Sparkenbaugh EM, Saini Y, Greenwood KK, Lapres JJ, **Luyendyk JP**, Copple BL, Maddox JF, Ganey PE, Roth RA. The Role of Hypoxia-Inducible Factor-1{alpha} in Acetaminophen Hepatotoxicity. *J Pharmacol Exp Ther.* 2011;338:492-502

046PRA - Kassel KM, Owens III AP, Rockwell CE, Sullivan BP, Wang R, Tawfik O, Li G, Guo GL, Mackman N and **Luyendyk JP**. Protease Activated Receptor-1 and Hematopoietic Cell Tissue Factor are Required for Hepatic Steatosis in Mice Fed a High Fat Diet. *Am. J. Pathol.* 2012. 179(5):2278-89.

047PRA - Mei S, Ni HM, Manley S, Bockus A, Kassel KM, **Luyendyk JP**, Copple BL and Ding WX. Differential Roles of Unsaturated and Saturated Fatty Acids on Autophagy and Apoptosis in Hepatocytes. *J. Pharmacol. Exp. Ther.*, 2012. 339(2):487-98.

048PRA - Owens III AP, Passam FH, Marshall SM, McDaniel AL, Rudel LL, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, **Luyendyk JP**, Moriarty PM, Nagarajan S, Furie B, Furie BC, Johns DG, Temel RE, Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. *J. Clin. Invest.*, 2012. 122(2): 558-68

049PRA - Kassel KM, Sullivan BP, **Luyendyk JP**. Lipopolysaccharide enhances transforming growth factor β 1-induced PDGF-B expression in bile duct epithelial cells. *J Gastroenterol. Hepatol.*, 2012. 27(4): 714-21.

050PRA - Sullivan BP, Copple BL, **Luyendyk JP**. Early growth response factor-1 limits biliary fibrosis in a model of xenobiotic-induced cholestasis in mice. *Toxicol. Sci.* , 2012 126(1): 267-74.

051PRA - Sullivan BP, Kassel KM, Jone A, Flick MJ, **Luyendyk JP**. Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury *Am. J Pathol.*, 2012 180(6):2321-9.

052PRA - Kassel KM, Sullivan BP, Cui W, Copple BL, **Luyendyk JP**. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. *Am. J Pathol.*, 2012. 181(4):1287-95.

053PRA - Sullivan BP, Kopec AK, Joshi N, Cline H, Brown JA, Bishop SC, Kassel KM, Rockwell C, Mackman N, **Luyendyk JP** (2012). Hepatocyte tissue factor activates the coagulation cascade in mice. *Blood.*, 121(10):1868-74.

054PRA - Antoniak S, Owens AP 3rd, Baunacke M, Williams JC, Lee RD, Weithäuser A, Sheridan PA, Malz R, **Luyendyk JP**, Esserman DA, Trejo J, Kirchhofer D, Blaxall BC, Pawlinski R, Beck MA, Rauch U, Mackman N. (2013). PAR-1 contributes to the innate immune response during viral infection. *J Clin Invest.* 123(3):1310-22.

055PRA - More VR, Xu J, Shimpi PC, Belgrave C, **Luyendyk JP**, Yamamoto M, Slitt AL. (2013). Keap1 knockdown increases markers of metabolic syndrome after long-term fat diet feeding. *Free Radic Biol Med.*, 16;61C:85-94.

056PRA - Li G, Kong B, Zhu Y, Zhan L, Williams JA, Tawfik O, Kassel KM, **Luyendyk JP**, Wang L, Guo GL (2013). Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. *Toxicol. Appl. Pharmacol.* 272(2):299-305.

057PRA- O'Brien KM, Allen KM, Rockwell CE, Towery K, **Luyendyk JP**, Copple BL. (2013). IL-17A Synergistically Enhances Bile Acid-Induced Inflammation during Obstructive Cholestasis. *Am J Pathol.* 183(5):1498-507.

058PRA- Li G, Zhu Y, Tawfik O, Kong B, Williams JA, Zhan L, Kassel KM, Luyendyk JP, Wang L, Guo GL. (2013). Mechanisms of STAT3 activation in the liver of FXR knockout mice. *Am J Physiol Gastrointest Liver Physiol.* 2013 Dec;305(11):G829-37.

059PRA- Rautou PE, Vion AC, **Luyendyk JP**, Mackman N. (2014). Circulating microparticle tissue factor activity is increased in patients with cirrhosis. *Hepatology.* 60:1793-5.

060PRA- Joshi N, Kopec AK, Towery K, Williams KJ, **Luyendyk JP**. (2014).The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. *J Pharmacol Exp Ther.* 349(3):383-92.

061PRA- Mochizuki A, Pace A, Rockwell CE, Roth KJ, Chow A, O'Brien KM, Albee R, Kelly K, Towery K, **Luyendyk JP**, Copple BL. (2014). Hepatic stellate cells orchestrate clearance of necrotic cells in a hypoxia-inducible factor-1 α -dependent manner by modulating macrophage phenotype in mice. *J Immunol.* 192(8):3847-57

062PRA- Kopec AK, **Luyendyk JP**. (2014). Coagulation in liver toxicity and disease: role of hepatocyte tissue factor. *Thromb Res.*133 Suppl 1:S57-9.

063PRA- Ni HM, Woolbright BL, Williams J, Copple B, Cui W, **Luyendyk JP**, Jaeschke H, Ding WX. (2014). Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. *J Hepatol.* 61(3):617-25.

064PRA- Raveendran VV, Kassel KM, Smith DD, **Luyendyk JP**, Williams KJ, Cherian R, Reed GA, Flynn CA, Csanaky IL, Lickteig AL, Pratt-Hyatt MJ, Klaassen CD, Dileepan KN. (2014). H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. *Am J Physiol Gastrointest Liver Physiol.* 307(2):G219-28.

065PRA- Lopez M, Kopec AK, Joshi N, Geddings JE, Cline H, Towery KL, Rockwell CE, Mackman N, **Luyendyk JP**. (2014). Fas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo. *Toxicol Sci.* 141(2):453-64.

066PRA- Kopec AK, Sullivan BP, Kassel KM, Joshi N, **Luyendyk JP**. (2014).Toxicogenomic analysis reveals profibrogenic effects of trichloroethylene in autoimmune-mediated cholangitis in mice. *Toxicol Sci.* 141(2):515-23.

067PRA- Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ, **Luyendyk JP**. (2014). Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. *J Pharmacol Exp Ther.* 351(2):288-97.

068PRA- Joshi N, Kopec AK, O'Brien KM, Towery KL, Cline-Fedewa H, Williams KJ, Copple BL, Flick MJ, **Luyendyk JP**. (2015). Coagulation-driven platelet activation reduces cholestatic liver injury and fibrosis in mice. *J Thromb Haemost.* Jan;13(1):57-71.

Associated commentary: J Thromb Haemost. 2015 Jan;13(1):54-6.

069PRA- Ellery PE, Maroney SA, Cooley BC, **Luyendyk JP**, Zogg M, Weiler H, Mast AE. (2015). A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. Blood. 125(26):4078-84.

070PRA- Miyakawa K, Joshi, N, Sullivan BP, Albee R, Brandenberger C, Jaeschke H, McGill MR, Scott MR, Ganey PE, Luyendyk JP, Roth RA (2015) Blood. In press.

Invited or non-peer-reviewed articles or reviews:

01NPRA - **Luyendyk JP** and Guo GL. Steatosis DeLIVERS high sensitivity C-reactive protein. Arterioscler Thromb Vasc Biol. 2011;31:1714-5

Books and book chapters: (Provide names of all authors, year, book title, chapter title, edition, publisher, and pages. If in press, provide documentation and PDF or book/book chapter if published the last five years.)

1) **Luyendyk JP**, Ganey PE, and Roth RA. Inflammation and Hepatotoxicity. In: Comprehensive Toxicology, 2nd Edition, Editor: Charlene McQueen. Elsevier Publishing Co: 2010

2. **Oral presentations in chronological order (oldest first, most recent last)**

Oral presentations subject to peer review before acceptance for inclusion in meeting program:

Luyendyk JP, Tencati M, Holscher T, and Mackman N. Modulation of LPS-induced inflammation and coagulation by the PI3K-Akt pathway. Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference. Chicago, IL. 2007.

Luyendyk JP, Tencati M, Holscher T, and Mackman N (2007). Modulation of LPS-induced cytokine and tissue factor expression in macrophages by the PI3K-Akt pathway. Toxicologist 96: 1869. Society of Toxicology Nation Meeting

Kassel KM, Sullivan BP, **Luyendyk JP** (2011). Lipopolysaccharide enhances TGF- β 1 induction of PDGF-B in bile duct epithelial cells: role of NF- κ B (see 029PA). Presenter: Karen M. Kassel. Experimental Biology Meeting, ASPET Molecular Pharmacology Division invited speaker.

Sullivan BP, Kassel KM, Manley S, and **Luyendyk JP**. (2011) Regulation of TGF- β 1-dependent integrin β 6 expression in bile duct epithelial cells. (see 027PA). Presenter: Bradley P. Sullivan. Experimental Biology Meeting, ASIP Program

Luyendyk JP, Owens III AP, Rockwell CE, Sullivan BP, Wang R, Tawfik O, Li G, Guo GL, Mackman N and Kassel KM. (2011) Protease Activated Receptor-1 and Hematopoietic Cell Tissue Factor are Required for Hepatic Steatosis in Mice Fed a High Fat Diet. Invited Speaker (Luyendyk)-abstract selected for short talk. FASEB Summer Conference. Proteases in hemostasis and vascular biology. Carefree, AZ.

Sullivan BP, Kassel KM, **Luyendyk JP** (2012) Fibrin(ogen)-Independent Role of Plasminogen Activators in Acetaminophen-Induced Liver Injury. Presenter: Bradley P. Sullivan. Society of Toxicology National Meeting

Sullivan BP, Kassel KM, **Luyendyk JP** (2012) Effect of trichloroethylene exposure on autoimmune-mediated cholangitis in NOD.c3c4 mice. Presenter: Bradley P. Sullivan. Experimental Biology Meeting, ASIP Program

Kassel KM, Sullivan BP, Copple BL **Luyendyk JP** (2012). Therapeutic administration of a direct thrombin inhibitor reduces hepatic inflammation in a mouse model of hypercholesterolemia. Presenter: James P. Luyendyk, ASIP Program.

Kopec AK, Kassel KM, Sullivan BP, and **Luyendyk JP** (2012). The thrombin inhibitor dabigatran inhibits high fat diet-induced obesity and fatty liver disease in mice. Presenter: Anna K. Kopec. American Heart Association Scientific Sessions.

Joshi N, Kopec AK, O'Brien KM, Towery KL, Cline-Fedewa H, Williams KJ, Copple BL, Flick MJ, **Luyendyk JP**. (2014). Coagulation driven platelet activation reduces injury and fibrosis in chronic liver disease. Experimental Biology. Presenter: Nikita Joshi, ASIP Program.

Joshi N, Kopec AK, O'Brien KM, Towery KL, Cline-Fedewa H, Williams KJ, Copple BL, Flick MJ, **Luyendyk JP**. (2014). Coagulation driven platelet activation reduces injury and fibrosis in chronic liver disease. Michigan Society of Toxicology. Presenter: Nikita Joshi.

Lopez M, Kopec AK, Joshi N, Geddings JE, Cline H, Towery KL, Rockwell CE, Mackman N, **Luyendyk JP**. (2014). Fas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo. Michigan Society of Toxicology. Presenter: Anna Kopec.

Kopec AK, Joshi N, Towery KL, Cline-Fedewa H, Flick MJ and Luyendyk JP (2015) Role of Fibrin(ogen) in Hepatocyte Proliferation after Acetaminophen Overdose. 2015 International Society of Thrombosis and Haemostasis Congress. Invited platform. Presenter: Anna Kopec

Joshi N, Kopec AK, Towery KL, Cline-Fedewa H, Flick MJ, and Luyendyk JP (2015) Fibrin(ogen) engagement of $\alpha\text{M}\beta\text{2}$ -integrin limits chronic liver fibrosis induced by a bile duct toxicant in mice. 2015 International Society of Thrombosis and Haemostasis Congress. Invited platform. Presenter: Nikita Joshi.

Oral presentations not subject to peer review before acceptance for inclusion in meeting program:

- 1. Luyendyk JP.** Tissue factor and the liver: match in a dynamite factory. 2009 University of Kansas Medical Center Liver Center Symposium, Kansas City, KS
- 2. Sullivan BP and Luyendyk JP.** The coagulation system contributes to $\alpha\text{V}\beta\text{6}$ integrin expression and liver fibrosis induced by cholestasis. 2010 University of Kansas Medical Center Liver Center Symposium, Kansas City, KS Presenter: Bradley P. Sullivan
- 3. Sullivan BP and Luyendyk JP.** P38 MAP Kinase is required for TGF- β1 -dependent Itg β6 mRNA induction in transformed human bile duct epithelial cells. 2010 University of Kansas Medical Center Student Research Forum, Kansas City, KS
- 4. Luyendyk JP, Kassel KM, Sullivan BP.** Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury. 2011 University of Kansas Medical Center Liver Center Symposium, Kansas City, KS. Presenter: Jim Luyendyk

Invited presentations and seminars:

- 1. Luyendyk JP** Inflammation and idiosyncratic drug reactions. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2004.
- 2. Luyendyk JP** Inflammation and idiosyncratic drug reactions. Department of Pharmacology and Toxicology,

University of Louisville, Louisville, KY. 2005

3. **Luyendyk JP.** Tissue factor and coagulation in chronic liver disease. University of North Carolina-Chapel Hill, Chapel Hill, NC. 2010
3. **Luyendyk JP.** Mechanisms of xenobiotic-induced biliary inflammation and fibrosis. ONES Symposium. National Institutes of Health Sciences, Research Triangle Park, NC. 2010
4. **Luyendyk JP.** Tissue factor and xenobiotic-induced cholestasis: the clot thickens. Central States Society of Toxicology Meeting, Iowa City, IA. 2010
5. **Luyendyk JP.** Tissue factor and coagulation proteases in chronic liver disease. Michigan State University, East Lansing, MI, 2011.
6. **Luyendyk JP.** Mechanisms of xenobiotic-induced biliary inflammation and fibrosis. ONES Symposium. National Institutes of Health Sciences, Research Triangle Park, NC. 2011
7. **Luyendyk JP.** Liv' er let die: coagulation decides. Invited speaker. Gordon Research Conference: Cellular and molecular mechanisms of toxicity. Proctor Academy, Andover, NH, 2011
8. **Luyendyk JP.** Role of the coagulation cascade in acute and chronic liver disease. University of Cincinnati, Hematology/Oncology Grand Rounds. Cincinnati, OH 2012.
9. **Luyendyk JP** Effect of trichloroethylene exposure on autoimmune-mediated cholangitis in NOD.c3c4 mice. ONES Symposium. National Institutes of Health Sciences, Research Triangle Park, NC. 2012
10. **Luyendyk JP** Effect of trichloroethylene exposure on autoimmune-mediated cholangitis in NOD.c3c4 mice. United States Environmental Protection Agency, National Center for Environmental Assessment, Research Triangle Park, NC. 2012.
11. **Luyendyk JP** Expression and Regulation of Tissue Factor on Hepatocytes. Invited speaker, Experimental Biology Meeting. American Society for Investigative Pathology Symposium. 2013
12. **Luyendyk JP** Liver let die: coagulation decides. Invited speaker, Experimental Biology Meeting, American Society for Pharmacology and Experimental Therapeutics. 2013.
13. **Luyendyk JP** Mechanisms coupling thrombin to liver disease pathogenesis. Pediatrics & Human Development, Division of Neonatology, Michigan State University, Sparrow Hospital, Lansing, MI. 2013
14. **Luyendyk JP** Role of blood coagulation in liver toxicity and disease. FASEB Summer Conference. Proteases in Hemostasis and Vascular Biology. 2013.
15. **Luyendyk JP** Mechanisms coupling thrombin to fatty liver disease: Basis for obesogenic effects of arsenic? ONES Symposium, National Institutes of Environmental Health Sciences. 2013.
16. **Luyendyk JP.** Coagulation-driven platelet activation in a mouse model of chronic biliary fibrosis. Blood Center of Wisconsin, 2014
17. **Luyendyk JP.** Hepatocyte tissue factor in liver pathology. 7th Annual Meeting on Hemostasis, University of North Carolina, Chapel Hill. 2014.
18. **Luyendyk JP.** Hepatoprotective effects of fibrin-integrin engagement in liver injury and fibrosis. ONES Symposium. National Institutes of Environmental Health, 2014.

19. **Luyendyk JP.** Mechanisms Coupling Coagulation to Fatty Liver Disease. Tamburro Symposium on Environmental Chemicals and Liver Disease. University of Louisville. 2014.
20. **Luyendyk JP.** Blood Coagulation in Liver Toxicity and Disease. University of Georgia at Athens, 2014.
21. **Luyendyk JP.** Coagulation protease activity and NAFLD/NASH pathogenesis. ASIP Program. Experimental Biology, 2015.
22. **Luyendyk JP.** Thrombin inhibitors and fatty liver disease. Boehringer Ingelheim, Biberach, Germany, 2015

23. **Luyendyk JP.** Context-dependent participation of fibrin(ogen) in experimental liver toxicity and disease. Invited SSC oral presentation. International Society of Thrombosis and Haemostasis. Toronto, Ontario, Canada
24. **Luyendyk JP.** Liver injury and intrahepatic coagulation. Coagulation in Liver Disease Conference VI. Charlottesville, VA. 2015